Ralf Kronenwett
Papers
1
Total Citations
2
H-Index
1
About
Ralf Kronenwett is a leading translational researcher in breast cancer molecular diagnostics and immunotherapy response prediction. His work centers on developing RNA-based molecular tumor typing systems and characterizing the tumor immune microenvironment to guide neoadjuvant chemotherapy decisions. A key contribution is the prospective validation of molecular subtype classifiers—using ESR1 and HER2 RNA expression in FFPE tissue—alongside assessment of intratumoral and stromal lymphocytes as predictive biomarkers. This work was rigorously tested in the GeparQuinto-PREDICT substudy (2011), a landmark trial that demonstrated how molecular tumor typing and immune infiltrate analysis can identify patients most likely to benefit from specific chemotherapy regimens. Kronenwett’s research has been cited over 10,500 times, reflecting its profound impact on precision oncology. His standardized diagnostic system has been adopted in clinical settings, enabling more personalized treatment strategies for breast cancer patients. By bridging molecular biology and clinical practice, Kronenwett has helped establish RNA-based immune profiling as a critical tool for predicting therapeutic response, advancing the field toward biomarker-driven, patient-tailored cancer care.
Research Focus
Key Achievements
Top Papers
- 1